Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
about
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal originAggressive variants of castration-resistant prostate cancerNovel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.Integrative molecular profiling of routine clinical prostate cancer specimens.SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatmentTMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.Markers for detection of prostate cancer.HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular surveyNutrigenetics and prostate cancer: 2011 and beyond.Histological variants of prostatic carcinoma and their significance.ERG protein expression as a biomarker of prostate cancer.Small cell carcinoma of the prostate.Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateDuctal adenocarcinoma of the prostate: Clinical and biological profiles.The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.Emerging Variants of Castration-Resistant Prostate Cancer.Potential for targeted therapy in prostate cancers with ERG abnormalities.TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimensERG gene rearrangements are common in prostatic small cell carcinomas.Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.Mucinous and secondary tumors of the prostate.SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.Neuroendocrine tumors of the prostate.Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.ERG rearrangement is present in a subset of transition zone prostatic tumorsInteractions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer
P2860
Q31005436-F9215758-D99A-46F9-A596-5660321DD057Q33693256-C8016B23-51B7-4E4E-9338-D9DF31CB1253Q34158217-02A9CE57-E926-44C4-8CA4-606E5E2CB734Q34411717-5DAE1863-8461-410A-A163-AEFA51A4563CQ35892022-77C721EC-2A10-4133-B446-D6CABEF41490Q35983468-382FDB10-6852-4BCD-AF10-E38B55A1A2ABQ36131601-62DD6534-F464-4C37-9F08-8E4E34E9635CQ36147719-94E12168-47FA-4BE8-9496-D9A26E1A8433Q36901964-F4519F04-1A5A-421C-9190-CA9243194C84Q37328403-13DB1D12-C8B2-4E2F-9F98-99CCEE58DBF5Q37705596-FDEFA16F-9B0E-4C0A-8D0B-5B4D95DFE023Q37885642-4DC42481-9A7A-4364-979B-795E4F67676DQ37972700-5AA8BE56-8D97-45A0-8D7E-ACF3EF17E24BQ38165243-61E774B8-87A6-42F5-8B24-6A47E18C3119Q38188869-2C711526-7DE9-45FB-978C-AE113418D769Q38377884-0CF48314-884C-4E3C-8388-601B724E968CQ38683009-D1D1339D-4834-47ED-96D3-2CA4D50F76C7Q38929364-B5BA1A88-49D5-4F09-8A48-85E7C8C8F7BCQ38930155-602D8908-96CD-436F-9CFF-59630E678FCDQ39033577-1B772461-F12C-402E-981A-2F9424C67CE2Q39210257-4CFE9BA5-8301-4189-AC47-6DF7A1985317Q39501622-7C9D7469-A1BF-4004-8F4E-69D028E533F5Q39577718-0A802A17-2054-4E27-89EF-48C0F95AAF80Q39666134-8D13A883-7976-43F8-9EE5-F73BB5A9EB14Q41052383-E33D1E8A-2183-4876-A0EC-706987DE1A63Q41628946-732DC7E8-E766-4A9A-91AA-07026CD34229Q42184220-27FF9AC9-B63E-4AD9-B909-493CE42C0015Q43247408-C01E0B55-4481-464C-AA49-A3BABBED186DQ47288076-C551161C-ED4D-4564-BEB2-B8F6FA7106C0Q47664729-CDD4E11D-79A0-47DF-AF76-463C094F55A1Q48030483-0DC83B80-638B-4890-99DE-32DFEEB41B8BQ49347811-43867196-D5FC-4903-8DFD-1DDBE6B62968Q51495262-1EB005AC-6CF3-49B8-B3E3-D737235728CBQ54403866-C7986F31-6209-46C2-B382-A7350E619EE4Q57693373-E9D83FD9-591A-4BCE-AE21-CDCD34475F5AQ57790298-372E5A6B-C1EF-4A4F-A2B8-59FC52EAD92B
P2860
Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@en
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@nl
type
label
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@en
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@nl
prefLabel
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@en
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@nl
P2093
P2860
P1433
P1476
Characterization of ETS gene a ...... ariants of prostate carcinoma.
@en
P2093
Arul M Chinnaiyan
Katherine A Linetzky
Khalid Suleman
Nishi Singhal
Rajal B Shah
Rohit Mehra
Scott A Tomlins
P2860
P2888
P304
P356
10.1038/MODPATHOL.2009.79
P577
2009-05-22T00:00:00Z
P5875
P6179
1029125989